{"id":9060,"date":"2020-07-09T09:15:00","date_gmt":"2020-07-09T07:15:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/"},"modified":"2026-05-05T22:12:05","modified_gmt":"2026-05-05T20:12:05","slug":"irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/","title":{"rendered":"IRLAB:s kliniska l\u00e4kemedelskandidat IRL752 publicerad i JPET"},"content":{"rendered":"
IRLAB meddelade idag att en vetenskaplig artikel som beskriver den unika farmakologiska profilen av IRL752, som utvecklas f\u00f6r behandling av balansneds\u00e4ttning och fall vid Parkinsons sjukdom, har blivit accepterad och nu publicerats online i The Journal of Pharmacology and Experimental Therapeutics, JPET.<\/strong><\/div>\n

\u201dDenna artikel var resultatet av ett lyckat samarbete mellan forskarna p\u00e5 IRLAB och en akademisk forskargrupp i Storbritannien. Att dela v\u00e5r forskning inom ett internationellt n\u00e4tverk och utforska potentialen av v\u00e5r l\u00e4kemedelskandidat hos ett erk\u00e4nt och oberoende labb som specialiserar sig p\u00e5 att studera kognitiva processer \u00e4r viktigt f\u00f6r oss. Jag skulle \u00e4ven vilja betona vikten av dessa vetenskapliga resultat f\u00f6r den fortsatta kliniska utvecklingen och den f\u00f6r\u00e4ndring vi hoppas att IRL752 kommer att inneb\u00e4ra f\u00f6r drabbade patienter och deras v\u00e5rdgivare\u201d, s\u00e4ger Stephan Hjorth, Ph.D., Prof., senior vetenskaplig r\u00e5dgivare p\u00e5 IRLAB. <\/span><\/span><\/span><\/span><\/span><\/p>\n

JPET, The Journal of Pharmacology and Experimental Therapeutics, <\/span><\/span><\/span><\/span><\/em>\u00e4r en h\u00f6gt rankad internationell tidskrift inom forskning kring farmakologi. <\/span><\/span><\/span><\/span>Tidskriften \u00e4r utgiven av The American Society for Pharmacology and Experimental Therapeutics (ASPET).<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n

IRL752 \u00e4r en l\u00e4kemedelskandidat i klinisk Fas II och utvecklas av IRLAB f\u00f6r behandling av balansneds\u00e4ttning (postural dysfunktion) och fall vid Parkinsons sjukdom (PD-Fall). Den vetenskapliga artikeln beskriver den farmakologiska profilen hos IRL752, karakteriserad av f\u00f6rst\u00e4rkning av kortikal noradrenalin, dopamin, och acetylkolin neurotransmission, \u00e5tf\u00f6ljt av f\u00f6rb\u00e4ttrade kognitiva funktioner. Denna farmakologiska profil \u00e4r i linje med den t\u00e4nkta kliniska anv\u00e4ndningen av IRL752 vid tillst\u00e5nd d\u00e4r kortikal neurotransmission \u00e4r f\u00f6rs\u00e4mrad, som axiala motorsymtom och kognitiva brister associerade med f\u00f6rs\u00e4mrad balans och fall vid Parkinsons sjukdom. Effektprofilen av IRL752 karakteriserades i omfattande in vivo-<\/em>studier, d\u00e4r effekt p\u00e5 beteende, neurotransmisson och genuttryck unders\u00f6ktes, samt i in vitro-<\/em>studier av receptorinteraktioner.<\/span><\/span><\/span><\/span><\/span><\/p>\n

Artikeln publicerades online som en del av JPET Fast Forward<\/em>, vilken inneh\u00e5ller artiklar i manuskriptform som har accepterats och publicerats i JPET<\/em> men som inte har redigerats och inte har tilldelats ett nummer av tidskriften. Redigering, inklusive grafik, kan leda till vissa skillnader mellan Fast Forward-versionen och den slutliga versionen.<\/span><\/span><\/span><\/span><\/span><\/p>\n

Artikeln: <\/span><\/span><\/span><\/span>Hjorth,\u00a0S. et al.<\/em> <\/span><\/span><\/span><\/span>(3S)<\/span><\/span><\/span><\/span>\u2010<\/span><\/span><\/span><\/span>3<\/span><\/span><\/span><\/span>\u2010<\/span><\/span><\/span><\/span>(2,3<\/span><\/span><\/span><\/span>\u2010<\/span><\/span><\/span><\/span>difluorophenyl)<\/span><\/span><\/span><\/span>\u2010<\/span><\/span><\/span><\/span>3<\/span><\/span><\/span><\/span>\u2010<\/span><\/span><\/span><\/span>methoxypyrrolidine (IRL752) \u2013 a novel cortical-preferring catecholamine transmission- and cognition-promoting agent. Journal of Pharmacology and Experimental Therapeutics<\/em>, <\/span><\/span><\/span><\/span>DOI: 10.1124\/jpet.120.000037<\/span><\/span><\/span><\/a>.<\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n

\n

F\u00f6r vidare information<\/strong><\/p>\n

Nicholas Waters, VD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Tel: +46 730 75 77 01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0\u00a0
E-post: nicholas.waters@irlab.se<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

IRLAB meddelade idag att en vetenskaplig artikel som beskriver den unika
\nfarmakologiska profilen av IRL752, som utvecklas f\u00f6r behandling av
\nbalansneds\u00e4ttning och fall vid Parkinsons sjukdom, har blivit accepterad och nu
\npublicerats online i The Journal of Pharmacology and Experimental Therapeutics,
\nJPET.<\/p>\n","protected":false},"template":"","class_list":["post-9060","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nIRLAB:s kliniska l\u00e4kemedelskandidat IRL752 publicerad i JPET - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB:s kliniska l\u00e4kemedelskandidat IRL752 publicerad i JPET - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB meddelade idag att en vetenskaplig artikel som beskriver den unika farmakologiska profilen av IRL752, som utvecklas f\u00f6r behandling av balansneds\u00e4ttning och fall vid Parkinsons sjukdom, har blivit accepterad och nu publicerats online i The Journal of Pharmacology and Experimental Therapeutics, JPET.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-05T20:12:05+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/\",\"url\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/\",\"name\":\"IRLAB:s kliniska l\u00e4kemedelskandidat IRL752 publicerad i JPET - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2020-07-09T07:15:00+00:00\",\"dateModified\":\"2026-05-05T20:12:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB:s kliniska l\u00e4kemedelskandidat IRL752 publicerad i JPET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB:s kliniska l\u00e4kemedelskandidat IRL752 publicerad i JPET - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB:s kliniska l\u00e4kemedelskandidat IRL752 publicerad i JPET - IRLAB","og_description":"IRLAB meddelade idag att en vetenskaplig artikel som beskriver den unika farmakologiska profilen av IRL752, som utvecklas f\u00f6r behandling av balansneds\u00e4ttning och fall vid Parkinsons sjukdom, har blivit accepterad och nu publicerats online i The Journal of Pharmacology and Experimental Therapeutics, JPET.","og_url":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/","og_site_name":"IRLAB","article_modified_time":"2026-05-05T20:12:05+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/","url":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/","name":"IRLAB:s kliniska l\u00e4kemedelskandidat IRL752 publicerad i JPET - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2020-07-09T07:15:00+00:00","dateModified":"2026-05-05T20:12:05+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/mfn_news\/irlabs-kliniska-lakemedelskandidat-irl752-publicerad-i-jpet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB:s kliniska l\u00e4kemedelskandidat IRL752 publicerad i JPET"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}